Action to Take: Buy Shares of MRCY

Action to Take: Buy Shares of Mercury Systems (MRCY)  On February 6, after the market closed, Mercury Systems (Nasdaq: MRCY) reported earnings for its second quarter 2024 fiscal year – for the period ending December 2023.  As is often the case with companies in a turnaround mode, the results were not good. In fact, company
Read More …

Action to Take: Sell Catalent at a Profit

On February 5, drug manufacturer Catalent (NYSE: CTLT) announced it would sell itself to Novo Nordisk (NYSE: NVO) for $63.50 per share in cash – about $11.5 billion in total.  This share price is a 17% premium to the prior closing price of $54.51 on Friday, February 2, and an increase of 40% since we
Read More …

This Is Spinal Tap

In this issue, we focus on a medical-device company that specializes in both orthopedic and spinal products used by doctors and surgeons across the globe. A mismanaged merger and other changes in strategy have sent the stock to record lows. Now, with an activist investor involved, we see good things happening for this company.
Read More …

An Under-the-Radar Defense Giant Set to Soar Higher

War is a growth industry in today’s world – in Ukraine, the Middle East, and many other fronts. The company we recommend in this issue is a key player in supplying defense technology including drones, fighter jets, and light tactical vehicles.
Read More …

Six corporate “spinoff” opportunities to consider now (from Barron’s on April 12)…

Barron’s reached out to Jim Osman, founder of research firm the Edge, which identifies opportunities in special situations, including spinoffs, mergers, management changes, and shareholder activism. Spinoffs, in particular, have been fertile ground in the past. Osman has been tracking them for 20-plus years and found that companies involved in spinoffs beat the market in
Read More …